← Back to patent-cliff list
QB0208-1
Tier C — Watch / tradeQB0208-1
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Benign prostatic hyperplasia, Hypercholesterolaemia, 糖尿病足溃疡, Ulcerative colitis
Regional status
US
-
EU
-
China
Phase II
2024-11-13
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of QB0208-1?
Approved indications include: Benign prostatic hyperplasia, Hypercholesterolaemia, 糖尿病足溃疡, Ulcerative colitis.
When does the QB0208-1 patent expire?
No public expiry year is available for QB0208-1 yet; this page updates once verified.
How do I get a quote for QB0208-1 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01